You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
|[amr-neisseria-gonorrhoeae](https://github.com/mcphersonlab/amr-neisseria-gonorrhoeae)| AMR in *N. gonorrhoeae*| IMARI Annual; CSIRO AMR Summit | The Lancet Infectious Diseases | npj Antimicrobials and Resistance |
64
65
|[amr-aspergillus-fumigatus](https://github.com/mcphersonlab/amr-aspergillus-fumigatus)| Azole resistance in *A. fumigatus*| MSGERC Biennial | Clinical Infectious Diseases | Journal of Antimicrobial Chemotherapy |
65
66
|[amr-lomentospora-prolificans](https://github.com/mcphersonlab/amr-lomentospora-prolificans)| Antifungal resistance in *L. prolificans*| MSGERC Biennial | Clinical Infectious Diseases | Antimicrobial Agents and Chemotherapy |
66
67
|[amr-hiv](https://github.com/mcphersonlab/amr-hiv)| HIV drug resistance | CROI Annual; ASV Annual; ESCV Annual | The Lancet HIV | Nature Microbiology |
67
68
|[amr-mycobacterium-tuberculosis](https://github.com/mcphersonlab/amr-mycobacterium-tuberculosis)| MDR-TB genomics | Global TB Summit (Qiagen) | The Lancet Infectious Diseases | npj Antimicrobials and Resistance |
68
69
|[amr-pseudomonas-aeruginosa](https://github.com/mcphersonlab/amr-pseudomonas-aeruginosa)| Multidrug-resistant *P. aeruginosa*| North American Cystic Fibrosis (CF) Conference | Clinical Infectious Diseases | npj Antimicrobials and Resistance |
69
-
|[tx-cap](https://github.com/mcphersonlab/tx-cap)| Treatment of community-acquired pneumonia | IDSA IDWeek | Clinical Infectious Diseases | The Lancet Infectious Diseases |
70
+
|[amr-env-food](https://github.com/mcphersonlab/amr-env-food)| Antimicrobial resistance in the food chain | CSIRO AMR Summit | Nature Microbiology | npj Antimicrobials and Resistance |
71
+
|[amr-env-water](https://github.com/mcphersonlab/amr-env-water)| Antimicrobial resistance in wastewater surveillance | CSIRO AMR Summit | Environmental Science & Technology | Water Research |
72
+
|[tx-cap](https://github.com/mcphersonlab/tx-cap)| Treatment of community-acquired pneumonia | IDSA IDWeek | Clinical Infectious Diseases | Antimicrobial Resistance & Infection Control |
70
73
|[tx-uuti](https://github.com/mcphersonlab/tx-uuti)| Treatment of uncomplicated urinary tract infections | IDSA IDWeek | Clinical Infectious Diseases | Journal of Antimicrobial Chemotherapy |
71
74
|[tx-staph-bacteremia](https://github.com/mcphersonlab/tx-staph-bacteremia)| Treatment of *Staphylococcal bacteremia*| ASHP Midyear | Clinical Infectious Diseases | Journal of Antimicrobial Chemotherapy |
72
75
|[tx-cdi](https://github.com/mcphersonlab/tx-cdi)| Treatment of *C. difficile* infection | 9th International *C. difficile* Symposium (ICDS) | Clinical Infectious Diseases | Gut Microbes |
73
76
|[mgx-virome](https://github.com/mcphersonlab/mgx-virome)| Gut virome characterization | ASV Annual; ESCV Annual | Nature Microbiology | Cell Host & Microbe |
74
-
|[mgx-mbx-abx-cdi](https://github.com/mcphersonlab/mgx-mbx-abx-cdi)| Metagenomic and metabolomic determinants of CDI | Houston *C diff* & Microbiome Conference | Gut Microbes | npj Biofilms and Microbiomes |
75
-
|[mgx-abx-healthy](https://github.com/mcphersonlab/mgx-abx-healthy)| Antibiotic effects on healthy gut microbiome | BSAC and GARDP Antimicrobial Chemotherapy Conference | Microbiome | Nature Communications |
77
+
|[mgx-cap](https://github.com/mcphersonlab/mgx-cap)| Pulmonary metagenomics of community-acquired pneumonia | IDSA IDWeek | Clinical Infectious Diseases | The Lancet Infectious Diseases |
78
+
|[mgx-mbx-abx-cdi](https://github.com/mcphersonlab/mgx-mbx-abx-cdi)| Metagenomic and metabolomic determinants of CDI | Houston *C diff* & Microbiome Conference | Nature Microbiology | Microbiome |
79
+
|[mgx-abx-healthy](https://github.com/mcphersonlab/mgx-abx-healthy)| Antibiotic effects on healthy gut microbiome | BSAC and GARDP Antimicrobial Chemotherapy Conference | Nature Communications | Microbiome |
|[mgx-mbx-colorectal-cancer](https://github.com/mcphersonlab/mgx-mbx-colorectal-cancer)| Microbiome and metabolome in colorectal cancer | AAAS Annual | Nature Medicine | Cell Host & Microbe |
78
-
|[mgx-mbx-glp-1](https://github.com/mcphersonlab/mgx-mbx-glp-1)| GLP-1 agonists and gut microbiome interactions | AAAS Annual | Nature Medicine | Gut |
79
-
|[ai-amr](https://github.com/mcphersonlab/ai-amr)| AI methods for antimicrobial resistance prediction | IMARI Annual | npj Antimicrobials and Resistance | Nature Machine Intelligence |
80
-
|[ai-forecast-influenza](https://github.com/mcphersonlab/ai-forecast-influenza)| AI forecasting of influenza dynamics | ASV Annual | The Lancet Infectious Diseases | Nature Communications |
82
+
|[mgx-mbx-glp-1](https://github.com/mcphersonlab/mgx-mbx-glp-1)| GLP-1 agonists and gut microbiome interactions | AAAS Annual | Nature Medicine | npj Biofilms and Microbiomes |
83
+
|[MicrobiomeHUES](https://github.com/mcphersonlab/MicrobiomeHUES)| Hierarchical Unified Ecological Spectrum of the human microbiome | ASM Microbe | Nature Microbiology | BMC Microbiology |
84
+
|[ai-amr](https://github.com/mcphersonlab/ai-amr)| AI methods for antimicrobial resistance prediction | IMARI Annual | Nature Machine Intelligence | npj Antimicrobials and Resistance |
85
+
|[ai-forecast-influenza](https://github.com/mcphersonlab/ai-forecast-influenza)| AI forecasting of influenza dynamics | ASV Annual | The Lancet Infectious Diseases | npj Digital Medicine |
|[ai-microbiome-transmission](https://github.com/mcphersonlab/ai-microbiome-transmission)| AI modeling of microbiome transmission | ASM Microbe | Nature Microbiology | Nature Communications |
87
+
|[ai-microbiome-transmission](https://github.com/mcphersonlab/ai-microbiome-transmission)| AI modeling of microbiome transmission | ASM Microbe | Nature Microbiology | npj Digital Medicine |
88
+
|[ai-structural-biology](https://github.com/mcphersonlab/ai-structural-biology)| Artificial intelligence methodology in structural biology | Biophysical Society Annual | Nature Methods | Nature Machine Intelligence |
89
+
|[MicroSCOPE](https://github.com/mcphersonlab/MicroSCOPE)| Microbial speciation from colony observation and prediction | ASM Microbe | Nature Microbiology | BMC Microbiology |
83
90
|[biophysics-proteins-as-complex-machines-of-physics](https://github.com/mcphersonlab/biophysics-proteins-as-complex-machines-of-physics)| Biophysical analysis of protein machinery | Biophysical Society Annual | Nature Structural & Molecular Biology | Biophysical Journal |
91
+
|[phys-hiv-lenacapavir](https://github.com/mcphersonlab/phys-hiv-lenacapavir)| Structure and physical properties of HIV-1 capsid hyperstabilization by lenacapavir | CROI Annual | Nature Structural & Molecular Biology | Journal of Virology |
84
92
|[structure-function-pharmacology](https://github.com/mcphersonlab/structure-function-pharmacology)| Structure-function relationships in pharmacology | IUPHAR Annual | Nature Reviews Drug Discovery | Molecular Pharmacology |
93
+
|[SpaceTime](https://github.com/mcphersonlab/SpaceTime)| Spatiotemporal model of receptors, enzymes, and pharmacology | IUPHAR Annual | Nature Reviews Drug Discovery | Molecular Pharmacology |
94
+
|[pcol-biofilm-rifamycins](https://github.com/mcphersonlab/pcol-biofilm-rifamycins)| Pharmacology of RNAP-targeting rifamycins on biofilms | IDSA IDWeek | Antimicrobial Agents and Chemotherapy | mBio |
95
+
|[pcol-vcddmde-hbv](https://github.com/mcphersonlab/pcol-vcddmde-hbv)| Pharmacology of DdmDE degradation of HBV cccDNA | AASLD Annual | Hepatology | Journal of Virology |
85
96
|[cost-amr](https://github.com/mcphersonlab/cost-amr)| Economic burden of antimicrobial resistance | Global AMR Innovators' Conference (GAMRIC) | The Lancet Infectious Diseases | Clinical Infectious Diseases |
86
97
|[roi-cdi](https://github.com/mcphersonlab/roi-cdi)| Return on investment analysis for CDI interventions | 9th International *C. difficile* Symposium (ICDS) | Clinical Infectious Diseases | Value in Health |
87
98
|[roi-pipeline-antimicrobial](https://github.com/mcphersonlab/roi-pipeline-antimicrobial)| ROI analysis for antimicrobial drug development | ISPOR Annual | Value in Health | Pharmacoeconomics |
88
99
|[EarthEpi](https://github.com/mcphersonlab/EarthEpi)| Environmental epidemiology and climate-health relationships | AAAS Annual | BMC Medicine | Nature Microbiology |
89
-
|[StormPath](https://github.com/mcphersonlab/StormPath)| Storm and weather impacts on infectious disease dynamics | AAAS Annual | Clinical Infectious Diseases | BMC Medicine |
100
+
|[StormPath](https://github.com/mcphersonlab/StormPath)| Storm and weather impacts on infectious disease dynamics | AAAS Annual | BMC Medicine | Clinical Infectious Diseases |
101
+
|[epi-hbv](https://github.com/mcphersonlab/epi-hbv)| Requirements of HBV elimination in the United States | AASLD Annual | Hepatology | The Lancet Infectious Diseases |
102
+
|[DigitalTwin-Society-Health](https://github.com/mcphersonlab/DigitalTwin-Society-Health)| Digital twin of society's health for implementation science | AAAS Annual | Nature Medicine | Implementation Science |
103
+
|[DOOR-STEP](https://github.com/mcphersonlab/DOOR-STEP)| Desirability of Outcome Ranking with Stratified Treatment Effect Profiling | IDSA IDWeek | Clinical Infectious Diseases | Statistics in Medicine |
104
+
|[PharmacyEducation](https://github.com/mcphersonlab/PharmacyEducation)| National trends in pharmacy education outcomes | AACP Annual | American Journal of Pharmaceutical Education | Academic Medicine |
105
+
|[pharm-comm-ai](https://github.com/mcphersonlab/pharm-comm-ai)| Interactive AI module for pharmacy student communication training | AACP Annual | Nature Medicine | npj Digital Medicine |
0 commit comments